Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 521 - 530 of 764 studies

Cancer and neoplasms

A PHASE II, RANDOMIZED, OPEN-LABEL STUDY EVALUATING TWO INAVOLISIB DOSE LEVELS IN COMBINATION WITH FULVESTRANT IN PARTICIPANTS WITH PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (WO46063 (optINAVO))

Oral and Gastrointestinal

Trial to Evaluate Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib in Participants With Moderately-to-Severely Active Crohn’s Disease (ZODIAC)

Oral and Gastrointestinal

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes) (N1T-MC-MALO (SYNERGY-Outcomes))

Blood

A MULTICENTER, RANDOMIZED, OPEN‑LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS (ZEBRHA-1)

Biopsy Investigation of Oxford Synovitis Cohort

Neurological

A Phase I, 2-Part Study to evaluate the safety, tolerability, pharmacokinets, and pharmacodynamics of single-ascending doses of intrathecally administered RG6496 in a randomized, placebo-controlled, investigator/participant-blind study with an open-label extension in Huntington's disease gene expansion carriers (POINT-HD)

Respiratory

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis. (M25-268)

Oral and Gastrointestinal

Master Protocol: A Phase 1b, non-randomized, open-label, repeat-dose, single center study utilizing a master protocol to investigate the safety and tolerability of multiple study interventions in advanced therapy naïve participants with moderate to severe ulcerative colitis. Sub Protocol: A Phase 1b, non-randomized, open-label, repeat-dose, single center study to investigate the safety and tolerability of aletekitug in advanced therapy naïve participants with moderate to severe ulcerative colitis. (PEGASUS)

Inflammatory and immune system

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA) (CHILL (QEL-005-CLN-01))

Cancer and neoplasms

CA266-0004: A Randomized Phase 2/3 Study of BMS-986545-01 (BNT327) in Combination with Chemotherapy Versus Standard of Care in Previously Untreated Participants with Unresectable, Metastatic, or Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)